

# 148 - References

## References

### Schizophrenia and related psychoses CHAPTER 1 References

1. Pillinger T, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry* 2020; 7:64-77.
2. Bak M, et al. Almost all antipsychotics result in weight gain: a meta-analysis. *PLoS One* 2014; 9:e94112.
3. Stamoula E, et al. Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA Adverse Event Reporting System database (FAERS). *Expert Opin Drug Saf* 2024; 23:239-245.
4. Marder SR, et al. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry* 2004; 161:1334-1349.
5. Cooper SJ, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. *J Psychopharmacol* 2016; 30:717-748.
6. Galletly C, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. *Aust N Z J Psychiatry* 2016; 50:410-472.
7. American Diabetes Association, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. *Diabetes Care* 2004; 27:596-601.
8. Vandenberghe F, et al. Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. *J Clin Psychiatry* 2015; 76:e1417-1423.
9. Lipkovich I, et al. Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. *BMC Psychiatry* 2008; 8:78.
10. Fitzgerald I, et al. Predicting antipsychotic-induced weight gain in first episode psychosis: a field-wide systematic review and meta-analysis of non-genetic prognostic factors. *Eur Psychiatry* 2023; 66:e42.
11. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults. Quality standard [QS80]. 2015 (last accessed February 2024); <https://www.nice.org.uk/guidance/qs80>.
12. Mitchell AJ, et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. *Psychol Med* 2012; 42:125-147.

13. Barnes TR, et al. Screening for the metabolic side effects of antipsychotic medication: findings of a 6-year quality improvement programme in the UK. *BMJ Open* 2015; 5:e007633.
14. Crawford MJ, et al. Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study. *Br J Psychiatry* 2014; 205:473-477.
15. Hammoudeh S, et al. Risk factors of metabolic syndrome among patients receiving antipsychotics: a retrospective study. *Community Ment Health J* 2020; 56:760-770.
16. Ward T, et al. Who is responsible for metabolic screening for mental health clients taking antipsychotic medications? *Int J Ment Health Nurs* 2018; 27:196-203.
17. Bruins J, et al. The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis. *PLoS One* 2014; 9:e112276.
18. Mizuno Y, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. *Schizophr Bull* 2014; 40:1385-1403.
19. Stroup TS, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). *Am J Psychiatry* 2011; 168:947-956.
20. Mukundan A, et al. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. *Cochrane Database Syst Rev* 2010; (12):CD006629.
21. Montes JM, et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. *Prog Neuropsychopharmacol Biol Psychiatry* 2007; 31:383-388.
22. Wu H, et al. Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials. *Schizophr Bull* 2022; 48:643-654.
23. Akinola PS, et al. Antipsychotic-induced metabolic syndrome: a review. *Metab Syndr Relat Disord* 2023; 21:294-305.
24. Galling B, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. *World Psychiatry* 2017; 16:77-89.
25. de Kuijper G, et al. Effects of controlled discontinuation of long-term used antipsychotics on weight and metabolic parameters in individuals with intellectual disability. *J Clin Psychopharmacol* 2013; 33:520-524.
26. Chen EY, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. *BMJ* 2010; 341:c4024.
27. Speyer H, et al. Reversibility of antipsychotic-induced weight gain: a systematic review and meta-analysis. *Front Endocrinol (Lausanne)* 2021; 12:577919.
28. Werneke U, et al. Behavioural management of antipsychotic-induced weight gain: a review. *Acta Psychiatr Scand* 2003; 108:252-259.
29. Caemmerer J, et al. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. *Schizophr Res* 2012; 140:159-168.
30. Rice J, et al. Integrative management of metabolic syndrome in youth prescribed second-generation antipsychotics. *Med Sci (Basel)* 2020; 8:34.

31. Vancampfort D, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. *World Psychiatry* 2019; 18:53-66.
32. Naslund JA, et al. Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: a systematic review and meta-analysis. *Gen Hosp Psychiatry* 2017; 47:83-102.

148 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 33. Mohanty K, et al. Effectiveness of lifestyle intervention on prevention/management of antipsychotic-induced weight gain among persons with severe mental illness: a systematic review and meta-analysis. *J Health Psychol* 2024; 29:690-706. 34. Lee K, et al. Antipsychotic-induced weight gain: exploring the role of psychiatrists in managing patients' physical health - challenges, current options and direction for future care. *BJPsych Bull* 2024; 48:24-29. 35. Manu P, et al. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. *Acta Psychiatr Scand* 2015; 132:97-108. 36. Kucukgoncu S, et al. Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials. *Obes Rev* 2017; 18:594-601. 37. Kim E, et al. A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia. *J Clin Psychopharmacol* 2008; 28:138-146. 38. Ratliff JC, et al. An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes. *Clin Schizophr Relat Psychoses* 2015; 8:196-200. 39. Praharaj SK, et al. Amantadine for olanzapine-induced weight gain: a systematic review and meta-analysis of randomized placebo-controlled trials. *Ther Adv Psychopharmacol* 2012; 2:151-156. 40. Zheng W, et al. Amantadine for antipsychotic-related weight gain: meta-analysis of randomized placebo-controlled trials. *J Clin Psychopharmacol* 2017; 37:341-346. 41. Zheng W, et al. Efficacy and safety of adjunctive aripiprazole in schizophrenia: meta-analysis of randomized controlled trials. *J Clin Psychopharmacol* 2016; 36:628-636. 42. Barak N, et al. A randomized, double-blind, placebo-controlled pilot study of betahistine to counteract olanzapine-associated weight gain. *J Clin Psychopharmacol* 2016; 36:253-256. 43. Lian J, et al. Ameliorating antipsychotic-induced weight gain by betahistine: mechanisms and clinical implications. *Pharmacol Res* 2016; 106:51-63. 44. Gadde KM, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. *Obes Res* 2001; 9:544-551. 45. Jain AK, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. *Obes Res* 2002; 10:1049-1056. 46. Tsoi DT, et al. Interventions for smoking cessation and reduction in individuals with schizophrenia. *Cochrane Database Syst Rev* 2013; 2:CD007253. 47. Weizman S, et al. A double-blind, placebo-controlled trial of bupropion add-on to olanzapine or risperidone in overweight individuals with schizophrenia. *J Clin Psychopharmacol* 2021; 41:629-631. 48. Greig SL, et al. Naltrexone ER/bupropion ER: a review in obesity management. *Drugs* 2015; 75:1269-1280. 49. Hinze-Selch D, et al. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. *Psychopharmacology (Berl)* 2000; 149:163-169. 50. Lu ML, et al. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: a 12-week, randomized, double-blind, placebo-controlled study. *Schizophr Res* 2017; 193:126-133. 51. Lu ML, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. *J Clin Psychiatry* 2004; 65:766-771. 52. Larsen JR, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. *JAMA Psychiatry* 2017; 74:719-728.

53. Mayfield K, et al. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. *J Psychopharmacol* 2016; 30:227–236. 54. Lee K, et al. A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. *Gen Hosp Psychiatry* 2022; 78:58–67. 55. Siskind D, et al. Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: a randomised controlled trial. *Diabetes Obes Metab* 2017; 20:1050–1055. 56. Ishoy PL, et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. *Diabetes Obes Metab* 2017; 19:162–171. 57. Agahi M, et al. Effect of melatonin in reducing second-generation antipsychotic metabolic effects: a double blind controlled clinical trial. *Diabetes Metab Syndr* 2017; 12:9–15. 58. Wang HR, et al. The role of melatonin and melatonin agonists in counteracting antipsychotic-induced metabolic side effects: a systematic review. *Int Clin Psychopharmacol* 2016; 31:301–306. 59. Porfirio MC, et al. Can melatonin prevent or improve metabolic side effects during antipsychotic treatments? *Neuropsychiatr Dis Treat* 2017; 13:2167–2174. 60. Zheng W, et al. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. *J Clin Psychopharmacol* 2015; 35:499–509. 61. Wang C, et al. Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: a randomized-controlled trial. *Ann Gen Psychiatry* 2020; 19:68. 62. Agarwal SM, et al. Pharmacological interventions for prevention of weight gain in people with schizophrenia. *Cochrane Database Syst Rev* 2022; 10:CD013337. 63. Stogios N, et al. Metformin for the prevention of clozapine-induced weight gain: a retrospective naturalistic cohort study. *Acta Psychiatr Scand* 2022; 146:190–200. 64. Anagnostou E, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial. *JAMA Psychiatry* 2016; 73:928–937.

Schizophrenia and related psychoses CHAPTER 1 65. Handen BL, et al. A randomized, placebo-controlled trial of metformin for the treatment of overweight induced by antipsychotic medication in young people with autism spectrum disorder: open-label extension. *J Am Acad Child Adolesc Psychiatry* 2017; 56:849–856.e6. 66. Chapman LE, et al. Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: a systematic review and meta-analysis. *Diabetes Metab* 2016; 42:316–327. 67. Henderson DC, et al. Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. *Schizophr Res* 2011; 130:53–56. 68. Roerig JL, et al. An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects. *Biol Psychiatry* 2009; 65:607–613. 69. Taveira TH, et al. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study. *J Psychopharmacol* 2014; 28:395–400. 70. Tek C, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept. *J Clin Psychopharmacol* 2014; 34:608–612. 71. Sjostrom L, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. *Lancet* 1998; 352:167–172. 72. Hilger E, et al. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. *J Clin Psychopharmacol* 2002; 22:68–70. 73. Pavlovic ZM. Orlistat in the treatment of clozapine-induced hyperglycemia and weight gain. *Eur Psychiatry* 2005; 20:520. 74. Carpenter LL, et al. A case series describing orlistat use in patients on psychotropic medications. *Med Health R I* 2004; 87:375–377. 75. Joffe G, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* 2008; 69:706–711.

76. Tchoukhine E, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. *J Clin Psychiatry* 2011; 72:326–330. 77. Chukhin E, et al. In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation. *Int Clin Psychopharmacol* 2013; 28:67–70. 78. Amrami-Weizman A, et al. The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients. *Psychopharmacology (Berl)* 2013; 230:23–27. 79. Gao J, et al. Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder. *Expert Rev Clin Pharmacol* 2022; 15:1011–1016. 80. Laguado SA, et al. Opioid antagonists to prevent olanzapine-induced weight gain: a systematic review. *Ment Health Clin* 2022; 12:254–262. 81. Meyer JM, et al. Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients. *CNS Spectr* 2023; 28:478–481. 82. Grywińska WB, et al. Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment. *Postep Psychiatr Neurol* 2023; 32:128–137. 83. Peng Z, et al. Effects of combined therapy of olanzapine and samidorphan on safety and metabolic parameters in schizophrenia patients: a meta-analysis. *Neuropsychiatr Dis Treat* 2023; 19:2295–2308. 84. Kahn RS, et al. Olanzapine/samidorphan in young adults with schizophrenia, schizophreniform disorder, or bipolar I disorder who are early in their illness: results of the randomized, controlled ENLIGHTEN-Early study. *J Clin Psychiatry* 2023; 84:22m14674. 85. Correll CU, et al. Reduction in multiple cardiometabolic risk factors with combined olanzapine/samidorphan compared with olanzapine: post hoc analyses from a 24-week phase 3 study. *Schizophr Bull* 2023; 49:454–463. 86. Prasad F, et al. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin: a case series. *Ther Adv Psychopharmacol* 2023; 13:20451253231165169. 87. Stogios N, et al. Antipsychotic--induced weight gain in severe mental illness: risk factors and special considerations. *Curr Psychiatry Rep* 2023; 25:707–721. 88. Correll CU, et al. Efficacy for psychopathology and body weight and safety of topiramate-antipsychotic cotreatment in patients with schizophrenia spectrum disorders: results from a meta-analysis of randomized controlled trials. *J Clin Psychiatry* 2016; 77:e746–e756. 89. Zheng W, et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. *Acta Psychiatr Scand* 2016; 134:385–398. 90. Buoli M, et al. The use of zonisamide for the treatment of psychiatric disorders: a systematic review. *Clin Neuropharmacol* 2017; 40:85–92.

---

Revision #1

Created 2026-01-04 20:12:49 UTC by Omar Ayman

Updated 2026-01-04 20:12:49 UTC by Omar Ayman